Noli Irritare Leones

Bipolar drug market “to plummet from 2011”

The market will be constrained over the next several years by the patent expiries and subsequent generic erosion of a number of key antipsychotic agents including AstraZeneca’s Seroquel (quetiapine fumarate), Eli Lilly’s Zyprexa (olanzapine), Bristol-Myers Squibb/Otsuka’s Abilify (aripiprazole) and Pfizer’s Geodon (ziprasidone), according to the study, from Decision Resources….

Moreover, patent expiries of branded antidepressants that include Wyeth’s – now Pfizer’s – Effexor XR (venlafaxine), Eli Lilly’s Cymbalta/Xeristar (duloxetine) and Forest/Lundbeck’s Lexapro/Cipralex (escitalopram) will further constrain the market, according to the report….

These patent expirations happen at various times between 2011 and 2018.

This entry was posted on Wednesday, November 11th, 2009 at 8:08 am and is filed under Bipolar Disorder. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.